Article citationsMore>>

Chapple, C.R., Martinez-Garcia, R., Selvaggi, L., Toozs-Hobson, P., Warnack, W., Drogendijk, T., Wright, D.M. and Bolodeoku, J. (2005) A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial. European Urology, 48, 464-470.
http://dx.doi.org/10.1016/j.eururo.2005.05.015

has been cited by the following article:

• TITLE: Dose Pattern Evolution and Therapeutic Benefit in Patients on Solifenacin or Fesoterodine Treatment in Daily Clinical Practice

  AUTHORS: José M. García-Mediero, Francisco Sánchez-Ballester, Daniel Arumi, Isabel Lizarraga

  KEYWORDS: Fesoterodine, Flexible-Dose, Overactive Bladder, Solifenacin

  JOURNAL NAME: Open Journal of Urology, Vol.6 No.6, June 14, 2016

  ABSTRACT: Aim: To explore in daily clinical practice the evolution in time of the fesoterodine and solifenacin dose pattern and assess the therapeutic benefit provided by the highest dose of these anti-muscarinics. Patients and Methods: This was a post-hoc analysis of data from an observational, cross-sectional, retrospective and multicenter study. Adult patients diagnosed with over active bladder (OAB) who initiated fesoterodine or solifenacin treatment were included. Data on the prescribed treatment and dose, change of dose, reasons for switching and treatment benefit were recorded. Results: A total of 828 subjects were analyzed (262 receiving solifenacin and 566 fesoterodine). Most subjects were women with a mean time since diagnosis of more than one year and aged around 60 years old. The majority of patients initiated the OAB treatment with the lowest available dose (64% fesoterodine vs. 77% solifenacin). At the follow-up visit 54% of the fesoterodine group and 66% of the solifenacin opted for dose escalation. At the study visit, 70.1% fesoterodine vs. 43.3% solifenacin remained on the highest dose. A significantly greater proportion of subjects receiving fesoterodine 8 mg, reported higher improvement in terms of both patient-reported-treatment benefit and clinical global impression compared with solifenacin 10 mg (p